Nanobiotix S.A.

Nanobiotix S.A. is a late-stage clinical biotechnology company that develops physics-based nanotherapeutics to improve treatment outcomes. The company's approach aims to create nanoparticles that can be combined with other drugs or therapies and integrate into clinical practice without adding burden. Nanobiotix operates with three distinct platforms. The Nanoradioenhancer platform is designed to increase the tumor-killing effect of radiotherapy while protecting healthy tissues. The Nanoprimer platform focuses on enabling effective extrahepatic delivery for innovative systemic therapeutic classes. The Neurological disease platform aims to address symptoms of neurological conditions by re-wiring the brain. The most advanced product candidate is JNJ-1900 (NBTXR3), which originated from the Nanoradioenhancer platform. JNJ-1900 (NBTXR3) is designed to address needs across various lines of therapy for solid tumors, rather than targeting specific patient populations with late-stage or metastatic cancer. The company believes JNJ-1900 (NBTXR3) could potentially improve the prognosis for up to 12 million patients receiving radiation therapy annually. To expand the development of JNJ-1900 (NBTXR3), Nanobiotix has entered into licensing agreements and strategic collaborations. In 2018, the company established a comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center ("MD Anderson"). This collaboration sponsors several Phase 1 and Phase 2 studies in the United States to evaluate JNJ-1900 (NBTXR3) across different tumor types and therapeutic combinations, with an expected enrollment of more than 300 patients across these clinical trials.